MX2019015527A - Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. - Google Patents

Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.

Info

Publication number
MX2019015527A
MX2019015527A MX2019015527A MX2019015527A MX2019015527A MX 2019015527 A MX2019015527 A MX 2019015527A MX 2019015527 A MX2019015527 A MX 2019015527A MX 2019015527 A MX2019015527 A MX 2019015527A MX 2019015527 A MX2019015527 A MX 2019015527A
Authority
MX
Mexico
Prior art keywords
compositions
texaphyrin
conjugates
platinum resistance
platinum
Prior art date
Application number
MX2019015527A
Other languages
English (en)
Inventor
Jonathan L Sessler
Jonathan Arambula
Zahid H Siddik
Gregory Thiabaud
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2019015527A publication Critical patent/MX2019015527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere a composiciones y conjugados unidos a platino (IV) y texafirina que comprenden una texafirina y un agente de platino (IV). La presente descripción también proporciona composiciones farmacéuticas de los conjugados y composiciones. Además, en la presente se proporcionan métodos para utilizar los presentes compuestos en el tratamiento de cáncer tal como un cáncer resistente a platino.
MX2019015527A 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. MX2019015527A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010841P 2014-06-11 2014-06-11
US201562135502P 2015-03-19 2015-03-19
PCT/US2015/035229 WO2015191797A1 (en) 2014-06-11 2015-06-11 Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance

Publications (1)

Publication Number Publication Date
MX2019015527A true MX2019015527A (es) 2022-06-17

Family

ID=54834283

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015527A MX2019015527A (es) 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2016016419A MX370673B (es) 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016016419A MX370673B (es) 2014-06-11 2015-06-11 Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.

Country Status (13)

Country Link
US (3) US10406167B2 (es)
EP (1) EP3154541A4 (es)
JP (3) JP7304128B2 (es)
KR (1) KR102412203B1 (es)
CN (2) CN116178456A (es)
AU (1) AU2015274589B2 (es)
BR (1) BR112016029024A8 (es)
CA (1) CA2950305C (es)
IL (1) IL249453B (es)
MX (2) MX2019015527A (es)
SG (1) SG11201610306RA (es)
WO (1) WO2015191797A1 (es)
ZA (1) ZA201608194B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015274589B2 (en) * 2014-06-11 2020-12-03 Board Of Regents, The University Of Texas System Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
US20190231888A1 (en) * 2016-10-03 2019-08-01 Board Of Regents, The University Of Texas System Texaphyrin and antitumor antibiotic conjugates
CN106543234B (zh) * 2016-10-14 2019-04-09 昆明理工大学 以饱和链为桥的手性双核铂配合物及其制备方法和应用
CN108732147B (zh) * 2018-04-23 2021-01-19 南京邮电大学 基于fret效应探测细胞凋亡过程的方法
AU2021326545A1 (en) 2020-08-14 2023-03-09 Board Of Regents, The University Of Texas System Texaphyrin derivatives for manganese chemotherapy, photoacoustic imaging, and photothermal therapy
CN114539320A (zh) * 2020-11-25 2022-05-27 北京大学 辐射激活的四价铂配合物及其用途
CN113292578A (zh) * 2021-05-21 2021-08-24 弗兰克·杰瑞·拉罗德 一种texaphyrin-叶酸螯合物及其制备方法与应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265823A (en) 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
US4980473A (en) 1985-01-18 1990-12-25 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
JPS62207283A (ja) 1986-03-07 1987-09-11 Yoshinori Kitani 新規な白金錯体
US5072011A (en) 1988-02-02 1991-12-10 Johnson Matthey, Inc. Pt(IV) complexes
US5272142A (en) 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5162509A (en) 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5252720A (en) 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5624919A (en) 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
US5409915A (en) 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US5633354A (en) 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US5756726A (en) 1995-06-02 1998-05-26 Pharmacyclics, Inc. Methods of producing singlet oxygen using compounds having improved functionalization
US5776925A (en) 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5955586A (en) * 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
AU7711096A (en) 1996-12-03 1998-06-29 Rijsuniversiteit Utrecht Cisplatinum comprising pharmaceutical
WO1999062551A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
EP1223982A2 (en) 1999-10-29 2002-07-24 Pharmacyclics, Inc. Conjugate for treating atheroma and other diseases
AU2001290580A1 (en) 2000-08-30 2002-03-13 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
FR2873037B1 (fr) 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CA2595236A1 (en) * 2005-01-19 2006-07-27 Pharmacyclics, Inc. A method for treating neurologic diseases
US8246967B2 (en) 2005-08-02 2012-08-21 Macdonnell Frederick M Compounds with modifying activity enhanced under hypoxic conditions
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
TW200728315A (en) 2005-12-06 2007-08-01 Nippon Chemical Ind Phosphorus transition-metal complex, method of producing the same, and anticancer agent forming the same
US20120164230A1 (en) 2007-05-08 2012-06-28 Rodney Feazell Soluble Nanoparticles as Delivery Systems for Prodrugs
WO2009021081A2 (en) 2007-08-06 2009-02-12 Ohio University Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
CN101125865B (zh) 2007-09-29 2010-09-08 广东药学院 手性钌配合物及其作为抗肿瘤药物的应用
US9265747B2 (en) 2008-08-26 2016-02-23 Massachusetts Institute Of Technology Platinum (IV) complexes for use in dual mode pharmaceutical therapy
CN102387797A (zh) 2009-03-20 2012-03-21 帕多瓦大学 以硫供体官能化的寡肽的金(iii)络合物及其用作抗肿瘤剂的用途
WO2011050575A1 (en) 2009-10-28 2011-05-05 The University Of Hong Kong Hydroxy-substituted gold(iii) porphyrin complexes as histone deacetylase inhibitors
CN102058576B (zh) 2010-12-28 2012-07-25 中国科学院深圳先进技术研究院 顺铂前体药物及其制备方法、核壳纳米颗粒及其制备方法
WO2012138988A2 (en) 2011-04-07 2012-10-11 The Research Foundation Of The City University Of New York Organometallic anti-cancer complexes
US9034862B2 (en) 2011-06-21 2015-05-19 Massachusetts Institute Of Technology Compositions and methods for the treatment of cancer
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
CN102408452B (zh) * 2011-12-13 2014-09-03 中山大学 四吡啶基卟啉桥联十字形四核铂配合物及其制备方法和抗肿瘤活性
US8729286B2 (en) 2012-05-10 2014-05-20 Massachusetts Institute Of Technology Platinum compounds as treatment for cancers, and related methods, kits, and compositions
US8828984B2 (en) 2012-11-19 2014-09-09 The University Of Hong Kong Gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
US9133225B2 (en) 2013-03-13 2015-09-15 Massachusetts Institute Of Technology Dual targeting anticancer agents
US9593139B2 (en) 2013-04-05 2017-03-14 Massachusetts Institute Of Technology Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety
AU2015274589B2 (en) 2014-06-11 2020-12-03 Board Of Regents, The University Of Texas System Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance

Also Published As

Publication number Publication date
ZA201608194B (en) 2023-05-31
JP2021102616A (ja) 2021-07-15
WO2015191797A1 (en) 2015-12-17
MX2016016419A (es) 2017-04-06
NZ726729A (en) 2023-08-25
IL249453B (en) 2021-01-31
CN116178456A (zh) 2023-05-30
US11389459B2 (en) 2022-07-19
JP2023078171A (ja) 2023-06-06
SG11201610306RA (en) 2017-01-27
BR112016029024A8 (pt) 2021-07-20
AU2015274589A1 (en) 2016-12-15
AU2015274589B2 (en) 2020-12-03
KR102412203B1 (ko) 2022-06-23
US10406167B2 (en) 2019-09-10
JP7304128B2 (ja) 2023-07-06
BR112016029024A2 (pt) 2017-08-22
CN106572991A (zh) 2017-04-19
EP3154541A1 (en) 2017-04-19
US20230113036A1 (en) 2023-04-13
EP3154541A4 (en) 2017-12-20
CA2950305A1 (en) 2015-12-17
US20170246182A1 (en) 2017-08-31
IL249453A0 (en) 2017-02-28
MX370673B (es) 2019-12-19
KR20170016933A (ko) 2017-02-14
US20200069698A1 (en) 2020-03-05
JP2017519004A (ja) 2017-07-13
CA2950305C (en) 2023-03-14

Similar Documents

Publication Publication Date Title
TW201613901A (en) New compounds
MY187540A (en) Compounds active towards bromodomains
PH12016501411A1 (en) Bifunctional cytotoxic agents
MX2016016419A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2016008448A (es) Conjugados de var2csa-farmaco.
GB201106750D0 (en) Novel compounds
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
GB201209613D0 (en) New compounds
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MY186311A (en) Bicyclic heterocycle compounds and their uses in therapy
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX366899B (es) Nuevos compuestos.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX2017002489A (es) Agentes terapeuticos humanos.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2017009608A (es) Compuestos anticancerigenos.